192 related articles for article (PubMed ID: 9748648)
1. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
Kreuzer KN
Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
[TBL] [Abstract][Full Text] [Related]
2. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
O'Reilly EK; Kreuzer KN
Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
[TBL] [Abstract][Full Text] [Related]
3. Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase.
Neece SH; Carles-Kinch K; Tomso DJ; Kreuzer KN
Mol Microbiol; 1996 Jun; 20(6):1145-54. PubMed ID: 8809767
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases.
Huff AC; Kreuzer KN
J Biol Chem; 1990 Nov; 265(33):20496-505. PubMed ID: 2173709
[TBL] [Abstract][Full Text] [Related]
5. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.
Hong G; Kreuzer KN
Mol Cell Biol; 2000 Jan; 20(2):594-603. PubMed ID: 10611238
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
Freudenreich CH; Chang C; Kreuzer KN
Cancer Res; 1998 Mar; 58(6):1260-7. PubMed ID: 9515814
[TBL] [Abstract][Full Text] [Related]
7. A bacteriophage model system for studying topoisomerase inhibitors.
Kreuzer KN
Adv Pharmacol; 1994; 29B():171-86. PubMed ID: 8996607
[TBL] [Abstract][Full Text] [Related]
8. Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli.
Huff AC; Leatherwood JK; Kreuzer KN
Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1307-11. PubMed ID: 2537494
[TBL] [Abstract][Full Text] [Related]
9. Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA.
Huff AC; Ward RE; Kreuzer KN
Mol Gen Genet; 1990 Mar; 221(1):27-32. PubMed ID: 2157956
[TBL] [Abstract][Full Text] [Related]
10. Repair of topoisomerase-mediated DNA damage in bacteriophage T4.
Stohr BA; Kreuzer KN
Genetics; 2001 May; 158(1):19-28. PubMed ID: 11333215
[TBL] [Abstract][Full Text] [Related]
11. Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes.
Woodworth DL; Kreuzer KN
Genetics; 1996 Jul; 143(3):1081-90. PubMed ID: 8807283
[TBL] [Abstract][Full Text] [Related]
12. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
13. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
14. Mutagenicity of topoisomerase-active agents in bacteriophage T4.
DeMarini DM; Lawrence BK
Teratog Carcinog Mutagen; 1988; 8(5):293-301. PubMed ID: 2905838
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.
Freudenreich CH; Kreuzer KN
EMBO J; 1993 May; 12(5):2085-97. PubMed ID: 8387918
[TBL] [Abstract][Full Text] [Related]
16. Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy.
Chourpa I; Morjani H; Riou JF; Manfait M
FEBS Lett; 1996 Nov; 397(1):61-4. PubMed ID: 8941714
[TBL] [Abstract][Full Text] [Related]
17. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
18. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
19. Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase.
Howard MT; Neece SH; Matson SW; Kreuzer KN
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12031-5. PubMed ID: 7991579
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
